Sweden

Nearly 50 medicines are now included in a Nordic pilot that relaxes language requirements on packaging to help improve access to essential hospital treatments.

Standing “shoulder to shoulder” can help alleviate difficult global market conditions, according to the Joint Nordic HTA Body.

Swedish biotech Affibody is using tiny engineered proteins to expand radioligand therapy's target space. CEO David Bejker details its HER2 program, Albumod technology and partnership strategy.

The Swedish biotech's LIB-01 offers eight-week efficacy from three-day dosing, targeting high discontinuation rates with current PDE5 inhibitors.

CEO Ahmed Mousa believes buloxibutid represents a real breakthrough.

Deal Snapshot: The US company has entered into another cancer drug transaction and bought Sprint's preclinical TREX1 program in a deal that could be worth around $400m.

Xbrane now expects to refile its Lucamzi biosimilar application in March 2026 after FDA manufacturing observations triggered a delay, pushing the potential approval date to September.

Following another complete response letter for its proposed US ranibizumab biosimilar, Xbrane Biopharma plans to finance new projects from its European biosimilar cash flows and rely on top-tier manufacturing partners to reduce regulatory risk.

In this episode of the In Vivo podcast, Sweden-based Cereno Scientific's CEO discusses how his company is turning to an old drug to help patients with rare cardiovascular and pulmonary diseases.

CEO Renée Aguiar-Lucander tells Scrip that the Swedish team is well-equipped to take its desensitisation treatment for the adult kidney transplant to market in the US.

The company’s approach leverages mPGES-1 inhibition to target both inflammation-related pain and lesion load. It is moving into a Phase II trial.

Orexo believes its data further demonstrates the ability of the AmorphOX powder-based intranasal formulation technology to develop formulations for large molecules.